Nuvation Bio Inc. rises amid market decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 18 2025
0mins
Should l Buy NUVB?
Source: 4
Nuvation Bio Inc. saw a price increase of 6.76%, breaking above its 5-day SMA, despite the broader market's downturn with the Nasdaq-100 down 0.70% and the S&P 500 down 0.02%.
This surge comes amid sector rotation as investors shift their focus to biotechnology stocks, which have shown resilience in challenging market conditions. The stock's performance is notable given the overall market weakness, indicating a potential shift in investor sentiment towards innovative biopharmaceutical companies.
The implications of this movement suggest that Nuvation Bio Inc. may be benefiting from a strategic repositioning within the biotech sector, attracting investors looking for growth opportunities in a volatile market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUVB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUVB
Wall Street analysts forecast NUVB stock price to rise
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.380
Low
8.00
Averages
11.38
High
18.00
Current: 4.380
Low
8.00
Averages
11.38
High
18.00
About NUVB
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nuvation Bio and Eisai Apply for Lung Cancer Drug Approval
- Application Accepted: The European Medicines Agency has accepted the Marketing Authorisation Application for taletrectinib filed by Nuvation Bio and Eisai, targeting non-small cell lung cancer, marking a significant advancement in the companies' oncology portfolio.
- Review Timeline: The application is assigned a standard review period of 210 'active' days, which will influence the drug's time to market and potentially create new revenue streams for the companies.
- Clinical Data Support: The application is backed by data from two pivotal Phase 2 studies, TRUST-I and TRUST-II, demonstrating taletrectinib's efficacy in treating non-small cell lung cancer, thereby enhancing market confidence in the drug.
- Current Market Status: Taletrectinib is already marketed as Ibtrozi in the US and Japan, and obtaining approval in the European market will significantly bolster Nuvation Bio and Eisai's global expansion strategy.
See More
Eisai and Nuvation Bio Submit Marketing Authorization Application for Taletrectinib to Treat Advanced ROS1-Positive Non-Small Cell Lung Cancer, Approved by the European Medicines Agency
Announcement of New Treatment: A new application for the treatment of advanced ROS1-positive non-small cell lung cancer has been validated by the European Medicines Agency.
Significance of Validation: This validation marks a significant step forward in the marketing authorization process for a promising cancer therapy.
See More
Nuvation Bio Under Investigation, Stock Plummets 25.3%
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Nuvation Bio Inc. investors regarding potential securities fraud or unlawful business practices by the company and its executives, which could further harm the company's reputation and stock price.
- Earnings Report Impact: On March 2, 2026, Nuvation reported its Q4 and full-year 2025 financial results, revealing that approximately 75% of treatment discontinuations occurred among later-line patient populations, which may negatively affect near-term revenue trends and investor confidence.
- Product Launch Challenges: During the commercial launch of IBTROZI (taletrectinib), Nuvation indicated that a significant share of early patient starts occurred in the third-line or later treatment settings, contributing to a gap between the number of patients starting treatment and net product revenue growth, potentially impacting future sales expectations.
- Severe Stock Reaction: On March 3, 2026, Nuvation's stock price fell by $1.48, or 25.3%, closing at $4.36 per share, reflecting market concerns regarding the company's financial health and future outlook.
See More
Nuvation Bio Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating Nuvation Bio Inc. for potential securities fraud by the company and certain officers, which could significantly impact investor rights and confidence.
- Earnings Report Insights: On March 2, 2026, Nuvation reported its Q4 and full-year 2025 financial results, revealing that approximately 75% of treatment discontinuations occurred among later-line patient populations, indicating a trend that may adversely affect near-term revenue.
- Product Launch Challenges: During the commercial launch of IBTROZI (taletrectinib), management noted that a significant share of early patient starts occurred in the third-line or later treatment settings, contributing to a gap between patient initiation and net product revenue growth, which could hinder overall financial performance.
- Stock Price Reaction: Following this news, Nuvation's stock price fell by $1.48, or 25.3%, closing at $4.36 per share on March 3, 2026, reflecting market concerns regarding the company's future outlook.
See More
IBTROZI Shows Unprecedented Durability in ROS1+ Lung Cancer Treatment
- Durability of Efficacy: IBTROZI has demonstrated a median Duration of Response (DOR) of 50 months in TKI-naïve patients with ROS1+ non-small cell lung cancer, showcasing its significant durability in treatment and reinforcing its position in oncology.
- Clinical Data Update: Upcoming presentations at the 2026 AACR Annual Meeting will highlight data from the TRUST-I and TRUST-II studies, emphasizing the efficacy and safety of IBTROZI in TKI-pretreated patients, which is expected to attract further attention and drive clinical adoption.
- FDA Approval Context: IBTROZI received FDA approval in June 2025 for the treatment of ROS1+ non-small cell lung cancer, marking a breakthrough in cancer therapy and likely enhancing Nuvation Bio's competitive edge in the market.
- Future Outlook: Nuvation Bio plans to continue evaluating IBTROZI's efficacy in future clinical studies, particularly in early-stage ROS1+ patients, which is anticipated to provide long-term growth potential for the company.
See More
IBTROZI Shows Unprecedented Durability in ROS1+ Lung Cancer Treatment
- Durability of Efficacy: IBTROZI has demonstrated a median Duration of Response (DOR) of 50 months in TKI-naïve patients with ROS1+ non-small cell lung cancer, showcasing its significant durability in treatment and reinforcing its position in oncology.
- Clinical Data Update: Upcoming presentations at the 2026 AACR Annual Meeting will highlight updated data from the TRUST-I and TRUST-II studies, emphasizing the efficacy and safety of IBTROZI in TKI-pretreated patients, which is expected to garner increased clinical interest.
- FDA Approval Context: IBTROZI received FDA approval in June 2025 for the treatment of ROS1+ non-small cell lung cancer, marking a significant milestone in cancer therapy and is anticipated to enhance the company's market performance moving forward.
- Future Outlook: Nuvation Bio plans to continue evaluating IBTROZI's efficacy in future clinical studies, particularly in early-stage ROS1+ patients, which is expected to create new growth opportunities for the company.
See More
Nuvation Bio and Eisai Apply for Lung Cancer Drug Approval
- Application Accepted: The European Medicines Agency has accepted the Marketing Authorisation Application for taletrectinib filed by Nuvation Bio and Eisai, targeting non-small cell lung cancer, marking a significant advancement in the companies' oncology portfolio.
- Review Timeline: The application is assigned a standard review period of 210 'active' days, which will influence the drug's time to market and potentially create new revenue streams for the companies.
- Clinical Data Support: The application is backed by data from two pivotal Phase 2 studies, TRUST-I and TRUST-II, demonstrating taletrectinib's efficacy in treating non-small cell lung cancer, thereby enhancing market confidence in the drug.
- Current Market Status: Taletrectinib is already marketed as Ibtrozi in the US and Japan, and obtaining approval in the European market will significantly bolster Nuvation Bio and Eisai's global expansion strategy.
See More
Eisai and Nuvation Bio Submit Marketing Authorization Application for Taletrectinib to Treat Advanced ROS1-Positive Non-Small Cell Lung Cancer, Approved by the European Medicines Agency
Announcement of New Treatment: A new application for the treatment of advanced ROS1-positive non-small cell lung cancer has been validated by the European Medicines Agency.
Significance of Validation: This validation marks a significant step forward in the marketing authorization process for a promising cancer therapy.
See More
Nuvation Bio Under Investigation, Stock Plummets 25.3%
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Nuvation Bio Inc. investors regarding potential securities fraud or unlawful business practices by the company and its executives, which could further harm the company's reputation and stock price.
- Earnings Report Impact: On March 2, 2026, Nuvation reported its Q4 and full-year 2025 financial results, revealing that approximately 75% of treatment discontinuations occurred among later-line patient populations, which may negatively affect near-term revenue trends and investor confidence.
- Product Launch Challenges: During the commercial launch of IBTROZI (taletrectinib), Nuvation indicated that a significant share of early patient starts occurred in the third-line or later treatment settings, contributing to a gap between the number of patients starting treatment and net product revenue growth, potentially impacting future sales expectations.
- Severe Stock Reaction: On March 3, 2026, Nuvation's stock price fell by $1.48, or 25.3%, closing at $4.36 per share, reflecting market concerns regarding the company's financial health and future outlook.
See More
Nuvation Bio Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating Nuvation Bio Inc. for potential securities fraud by the company and certain officers, which could significantly impact investor rights and confidence.
- Earnings Report Insights: On March 2, 2026, Nuvation reported its Q4 and full-year 2025 financial results, revealing that approximately 75% of treatment discontinuations occurred among later-line patient populations, indicating a trend that may adversely affect near-term revenue.
- Product Launch Challenges: During the commercial launch of IBTROZI (taletrectinib), management noted that a significant share of early patient starts occurred in the third-line or later treatment settings, contributing to a gap between patient initiation and net product revenue growth, which could hinder overall financial performance.
- Stock Price Reaction: Following this news, Nuvation's stock price fell by $1.48, or 25.3%, closing at $4.36 per share on March 3, 2026, reflecting market concerns regarding the company's future outlook.
See More
IBTROZI Shows Unprecedented Durability in ROS1+ Lung Cancer Treatment
- Durability of Efficacy: IBTROZI has demonstrated a median Duration of Response (DOR) of 50 months in TKI-naïve patients with ROS1+ non-small cell lung cancer, showcasing its significant durability in treatment and reinforcing its position in oncology.
- Clinical Data Update: Upcoming presentations at the 2026 AACR Annual Meeting will highlight data from the TRUST-I and TRUST-II studies, emphasizing the efficacy and safety of IBTROZI in TKI-pretreated patients, which is expected to attract further attention and drive clinical adoption.
- FDA Approval Context: IBTROZI received FDA approval in June 2025 for the treatment of ROS1+ non-small cell lung cancer, marking a breakthrough in cancer therapy and likely enhancing Nuvation Bio's competitive edge in the market.
- Future Outlook: Nuvation Bio plans to continue evaluating IBTROZI's efficacy in future clinical studies, particularly in early-stage ROS1+ patients, which is anticipated to provide long-term growth potential for the company.
See More
IBTROZI Shows Unprecedented Durability in ROS1+ Lung Cancer Treatment
- Durability of Efficacy: IBTROZI has demonstrated a median Duration of Response (DOR) of 50 months in TKI-naïve patients with ROS1+ non-small cell lung cancer, showcasing its significant durability in treatment and reinforcing its position in oncology.
- Clinical Data Update: Upcoming presentations at the 2026 AACR Annual Meeting will highlight updated data from the TRUST-I and TRUST-II studies, emphasizing the efficacy and safety of IBTROZI in TKI-pretreated patients, which is expected to garner increased clinical interest.
- FDA Approval Context: IBTROZI received FDA approval in June 2025 for the treatment of ROS1+ non-small cell lung cancer, marking a significant milestone in cancer therapy and is anticipated to enhance the company's market performance moving forward.
- Future Outlook: Nuvation Bio plans to continue evaluating IBTROZI's efficacy in future clinical studies, particularly in early-stage ROS1+ patients, which is expected to create new growth opportunities for the company.
See More
